299
Views
12
CrossRef citations to date
0
Altmetric
Letter to the Editor

Resolution of Acanthamoeba Keratitis with Adjunctive Use of Oral Miltefosine

, MD, , MD, , MD, , MD, , BA, , OD, , MD, , MD & , MD show all
Pages 278-281 | Received 12 Feb 2019, Accepted 18 Nov 2019, Published online: 12 Dec 2019

References

  • Carnt N, Hoffman JJ, Verma S, et al. Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors. Br J Ophthalmol. 2018;102:1621–1628. doi:10.1136/bjophthalmol-2018-312544. [Epub ahead of print].
  • Jiang C, Sun X, Wang Z, et al. Acanthamoeba keratitis: clinical characteristics and management. Ocul Surf. 2015;13:164–168. doi:10.1016/j.jtos.2015.01.002.
  • Yoder JS, Verani J, Heidman N, et al. Acanthamoeba keratitis: the persistence of cases following a multistate outbreak. Ophthalmic Epidemiol. 2012;19:221–225. doi:10.3109/09286586.2012.681336.
  • Tu EY. Acanthamoeba keratitis: a new normal. Am J Ophthalmol. 2014;158:417–419. doi:10.1016/j.ajo.2014.06.007.
  • Alkharashi M, Lindsley K, Law HA, et al. Medical interventions for Acanthamoeba keratitis. Cochrane Database Syst Rev. 2015;2:CD010792.
  • Polat ZA, Obwaller A, Vural A, et al. Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. Parasitol Res. 2012;110:515–520. doi:10.1007/s00436-011-2515-0.
  • Cojean S, Houze S, Haouchine D, et al. Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis. 2012;18:704–706. doi:10.3201/eid1804.110841.
  • Santa-Rita RM, Santos Barbosa H, Meirelles MN, et al. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 2000;75:219–228. doi:10.1016/S0001-706X(00)00052-8.
  • Blaha C, Duchene M, Aspock H, Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother. 2006;57:273–278. doi:10.1093/jac/dki417.
  • Seifert K, Duchene M, Wernsdorfer WH, et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother. 2001;45:1505–1510. doi:10.1128/AAC.45.5.1505-1510.2001.
  • Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol. 2009;148:487–499. doi:10.1016/j.ajo.2009.06.009.
  • Martín-Navarro CM, López-Arencibia A, Arnalich-Montiel F, et al. Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba. Graefes Arch Clin Exp Ophthalmol. 2013;251:2111–2117. doi:10.1007/s00417-013-2371-y.
  • Tu EY, Joslin CE, Shoff ME. Successful treatment of chronic stromal acanthamoeba keratitis with oral voriconazole monotherapy. Cornea. 2010;29:1066–1068. doi:10.1097/ICO.0b013e3181cbfa2c.
  • Verweij J, Krzemieniecki K, Kok T, et al. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult – an EORTC soft tissue and bone sarcoma group study. Eur J Cancer. 1993;29A:208–209. doi:10.1016/0959-8049(93)90177-H.
  • Planting AS, Stoter G, Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer. 1993;29A:518–519. doi:10.1016/S0959-8049(05)80142-X.
  • Thomas PC, Dorlo MB, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67:112576–112597.
  • Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag. 2007;3:733–740.
  • Robaei D, Carnt N, Minassian DC, et al. The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. Ophthalmology. 2014;121:1383–1388. doi:10.1016/j.ophtha.2014.01.031.
  • Polat ZA, Walochnik J, Obwaller A, et al. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. Clin Exp Ophthalmol. 2014;42:151–158. doi:10.1111/ceo.2014.42.issue-2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.